Sarah Danson

We are open to recruitment in Sheffield

The Arts Tower with trees and Weston Park in the foreground

The National Student Survey results are in and we're proud to say that we're top of the Russell Group for the third year in a row! And our Student's Union has been ranked number 1 once again.

A testament to the hard work of our brilliant University community 👏🎉

sheffield.ac.uk/news/sheffie...

NHS innovation ‘at risk’ as university partnerships deprioritised Report highlights fragmentation of academic links with health system as research drops off NHS agenda

Proportion of NHS doctors who carry out research has fallen by a quarter over 13 years despite evidence suggesting hospitals with active research programmes deliver better patient outcomes, finds @policyatkings.bsky.social www.timeshighereducation.com/news/nhs-inn... via @helenpacker.bsky.social

Impressive poster from Dr Sophie Williams @sheffielduni.bsky.social on the microenvironment in GBM. Also her Supervisor @sdanson1.bsky.social #SMPHResearch&Innovation

This is superb news. Something to really celebrate. Thanks to all involved

Great work from Sophie Williams on brain ageing in the glioblastoma tumour microenvironment

Sheffield Ex Vivo Group out in force at Sheffield #smph_research&innovation meeting today. Callum Blee, Louis Lane and Jamie Adams pictured. Great to see

Announcement image - dark blue background with coloured overlapping circles Top shows the Cancer Research UK Manchester Institute Logo Centre shows a photograph of Professor Samra Turajlić Text says: "A warm welcome to our new Director, Professor Samra Turajlić, from all staff and students at the Cancer Research UK Manchester Institute"

We are delighted to announce, along with Cancer Research UK (@cancerresearchuk.org), The University of Manchester (@manchester.ac.uk) and The Christie NHS Foundation Trust, the appointment of Professor Samra Turajlić as our new Director! ⭐

Full story here: www.cruk.manchester.ac.uk/news/profess...

Enjoyed today. Looking forward to hearing more tomorrow

Christine Le Maitre opening our annual meeting #SMPH_Research&Innovation. Apologies I cannot rotate!!

Exciting opportunity to join the cancer research community in Sheffield!!

Huge congratulations, Jim

Didn't I just see you in person??

Yesterday, Professor Sarah Danson presented the results of the UK DANTE trial at the 2025 American Society of Clinical Oncology (ASCO) annual medical meeting.

Read more: buff.ly/arneMoo

#melanoma #melanomacancer #ASCO25

Honoured to present the DANTE trial at ASCO today on behalf of the extended DANTE team. Thank you to all the patients who were involved

Much less clarity on whether or not to continue systemic immunotherapy after pCR following neoadjuvant therapy

The people have spoken, and they are undedecided - more work to do! #melsm #ASCO25

Great to meet up with Sheffield colleagues, Sophie Trotter and Syed Hussain at #ASCO25

Sophie Trotter at #ASCO25 presenting frailty measures from the STAR renal cell cancer trial @fohsheffield.bsky.social @sheffieldteachinghospitals @universityofleeds.bsky.social

Data from randomized Ph 3 trial that studied time of day of immunotherapy infusion said that infusion before 3:00 PM is far superior to > 3:00 PM. Study by Yongchang Zhang & team. Circadian rhythms with potential major impact on T cell circulation & exhaustion. h/t @stephenvliu.bsky.social #ASCO25

Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO
Jan Mehnert @nyulangone.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Melanoma rapid #3 ➡️ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8%

Took 400 patients screened to enroll 45 🤔

Yiufan Qiu @mdanderson.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social

Metastatic mucosal melanoma today:
-combination immunotherapy shows lackluster efficacy
-MEKi with 25% ORR
-KIT + anti PD1 with 54.8% ORR
-triplet ICI with 33% ORR
-lenv pembro with 50% ORR
-TIL with 50% ORR
Jun Guo
#ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social

This is fascinating. When paired with the Manchester abstract @beckilee.bsky.social and colleagues presented, do we need to change practice now?

Also please contact ctrad@macmillan.org for a sign up form so you can be kept up to date with CT RAD activities, meetings and opportunities @ctrad.bsky.social @icr.ac.uk @profemmahall.bsky.social @montefiored.bsky.social

News for UK radiotherapy community.
Pleased to say that thanks to @macmillancancer we have been able to establish #ctrad.
We plan a proposals guidance meeting on 8.7.25
If you have a new trial idea and wish to attend please contact ctrad@macmillan.org to register

Well done @catrionamayland.bsky.social on this important work. Go Sheffield researchers @sheffielduni.bsky.social!

ONLINE Zoom Webinar

Free to all UKONS members!

This webinar will demystify the process behind the UKONS conference submission process with tips from previous winners.

Chaired by:
Dr Jo Bird, Research MIG Lead

web-eur.cvent.com/event/4cdaed...

#UKONSwebinar #Publication

📣Today marks the start of Melanoma Awareness Month 2025! There are a variety of ways that you can get involved throughout May 👉 buff.ly/3N8ELve

Let’s reach as many people as possible and make a real difference.💙

#melanomaskincancer #melanomaawarenessmonth

☀️ Here are some worrying statistics that have come out of our recent public survey.

Melanoma skin cancer rates continue to climb in the UK, the implications of these findings are significant.

You can read more here 👉 buff.ly/6eT6MkF

#MelanomaAwarenessmonth

May is Melanoma Awareness Month, a brilliant opportunity for us to come together to raise awareness of melanoma.

Get prepared by downloading our communications toolkit👉https://buff.ly/BcV1bNi

Let’s reach as many people as possible and make a real difference.💙

#melanoma